

Status: Currently Official on 15-Feb-2025  
Official Date: Official as of 01-May-2018  
Document Type: USP Monographs  
DocId: GUID-5485BBC7-0B21-494F-B907-92443B9815A1\_3\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M46740\\_03\\_01](https://doi.org/10.31003/USPNF_M46740_03_01)  
DOI Ref: co9qg

© 2025 USPC  
Do not distribute

## Magnesium Citrate Oral Solution

### DEFINITION

Magnesium Citrate Oral Solution is a sterilized or pasteurized solution containing NLT 7.59 g of anhydrous citric acid ( $C_6H_8O_7$ ) and an amount of magnesium citrate equivalent to NLT 1.55 g and NMT 1.9 g of magnesium oxide (MgO) in each 100 mL of Oral Solution.

Prepare Magnesium Citrate Oral Solution as follows.

Magnesium Carbonate	15 g
Anhydrous Citric Acid	27.4 g
Syrup	60 mL
Talc	5 g
Lemon Oil	0.1 mL
Potassium Bicarbonate	2.5 g
Purified Water, a sufficient quantity to make	350 mL

Dissolve the *Anhydrous Citric Acid* in 150 mL of hot *Purified Water* in a suitable dish, slowly add the *Magnesium Carbonate* previously mixed with 100 mL of *Purified Water*, and stir until it is dissolved. Add the *Syrup*, heat the mixed liquids to the boiling point, and immediately add the *Lemon Oil* previously triturated with *Talc*. Filter the mixture, while hot, into a strong bottle of suitable capacity previously rinsed with boiling *Purified Water*. Add boiled *Purified Water* to bring the preparation to final volume. Use *Purified Cotton* as a stopper for the bottle, and allow to cool. Add the *Potassium Bicarbonate*, and immediately insert the stopper in the bottle securely. Shake the solution occasionally until the *Potassium Bicarbonate* is dissolved, cap the bottle, and sterilize or pasteurize the solution.

Alternatively, 30 g of citric acid containing 1 molecule of water of hydration, equivalent to 27.4 g of *Anhydrous Citric Acid*, may be used in the foregoing formula. In this process, replace the 2.5 g of *Potassium Bicarbonate* with 2.1 g of sodium bicarbonate, preferably in tablet form. The Oral Solution may be further carbonated by the use of carbon dioxide under pressure.

### IDENTIFICATION

- A. [IDENTIFICATION TESTS—GENERAL, Magnesium\(191\)](#): Meets the requirements
- B.

**Sample:** 5 mL

**Analysis:** To the *Sample* add 1 mL of potassium permanganate TS and 5 mL of mercuric sulfate TS, and heat the solution.

**Acceptance criteria:** A white precipitate is formed.

### ASSAY

#### • CITRIC ACID

**Mobile phase, Standard preparation 1, and Chromatographic system:** Proceed as directed in [Assay for Citric Acid/Citrate and Phosphate \(345\)](#).

**Assay preparation:** Transfer 10 mL of Oral Solution that has been previously freed from excessive carbon dioxide by repeated pouring to a suitable volumetric flask, and proceed as directed in [Assay for Citric Acid/Citrate and Phosphate \(345\)](#), Assay Preparation for Citric Acid/Citrate Assay.

**Analysis:** Proceed as directed in [Assay for Citric Acid/Citrate and Phosphate \(345\)](#), Procedure.

Calculate the quantity, g, of anhydrous citric acid ( $C_6H_8O_7$ ) in 100 mL of Oral Solution:

$$\text{Result} = (r_u/r_s) \times C_s \times V \times D \times (M_{r1}/M_{r2}) \times F$$

$r_u$  = peak area of citrate from the Assay preparation

$r_s$  = peak area of citrate from Standard preparation 1

$C_s$  = concentration of citrate in Standard preparation 1 (μg/mL)

$V$  = final volume of Oral Solution, 100 mL

$D$  = dilution factor

$M_{r1}$  = molecular weight of citric acid ( $C_6H_8O_7$ ), 192.12

$M_{r2}$  = molecular weight of citrate ( $C_6H_5O_7$ ), 189.10

$F$  = conversion factor,  $10^{-6}$  g/μg

**Acceptance criteria:** NLT 7.59 g in 100 mL of Oral Solution

• **MAGNESIUM OXIDE**

**Sample:** 50.0 mL of Oral Solution that has been previously freed from excessive carbon dioxide by repeated pouring

**Analysis:** Transfer the Sample to a 100-mL volumetric flask, and dilute with water to volume. Transfer 5.0 mL of the resulting solution to a beaker containing 150 mL of water heated to 70°–80°, and add 1 mL of ammonium chloride TS and 3 mL of ammonium hydroxide. Mix, and slowly add 8 mL of 8-hydroxyquinoline TS with stirring. After standing for 30 min, filter through a sintered-glass crucible, previously dried and weighed, and wash the precipitate with ten 10-mL portions of water. Dry the crucible and contents at 105° for 3 h, cool, and weigh. Determine the equivalent of magnesium oxide (MgO) in 100 mL of Oral Solution by multiplying the weight of  $C_{18}H_{12}MgN_2O_2 \cdot 2H_2O$  so obtained by 4.624.

**Acceptance criteria:** 1.55–1.9 g in 100 mL of Oral Solution

**IMPURITIES**

• [CHLORIDE AND SULFATE, Chloride \(221\)](#).

**Sample:** 2.0 mL

**Acceptance criteria:** 0.01%; it shows no more chloride than corresponds to 0.30 mL of 0.020 N hydrochloric acid.

• [CHLORIDE AND SULFATE, Sulfate\(221\)](#).

**Sample:** 2.0 mL

**Acceptance criteria:** 0.015%; it shows no more sulfate than corresponds to 0.30 mL of 0.020 N sulfuric acid.

• **TARTARIC ACID**

**Sample:** 10 mL

**Analysis:** Place the Sample in a test tube, add 1 mL of glacial acetic acid and 3 mL of a solution of potassium acetate (1 in 2), shake the mixture vigorously, then gently rub the inner wall of the test tube with a glass rod for a few min, and allow to stand for 1 h.

**Acceptance criteria:** No white, crystalline precipitate soluble in 6 N ammonium hydroxide is formed.

**ADDITIONAL REQUIREMENTS**

• **PACKAGING AND STORAGE:** Package in bottles NLT 200 mL in capacity. Store at controlled room temperature or in a cool place.

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
MAGNESIUM CITRATE COMPOUNDED ORAL SOLUTION	<a href="#">Brian Serumaga</a> Science Program Manager	CMP2020 Compounding 2020
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	CMP2020 Compounding 2020

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 31(2)

Current DocID: [GUID-5485BBC7-0B21-494F-B907-92443B9815A1\\_3\\_en-US](#)

Previous DocID: [GUID-5485BBC7-0B21-494F-B907-92443B9815A1\\_1\\_en-US](#)

DOI: [https://doi.org/10.31003/USPNF\\_M46740\\_03\\_01](https://doi.org/10.31003/USPNF_M46740_03_01)

DOI ref: [co9qq](#)

OFFICIAL